Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation-Reference-Cited by-同舟云学术

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation

Published:2024-08-08 Issue:1 Volume:15 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Stokes Matthew E.,Wenzl Kerstin,Huang C. Chris^ORCID,Ortiz María,Hsu Chih-Chao,Maurer Matthew J.^ORCID,Stong Nicholas^ORCID,Nakayama Yumi^ORCID,Wu Lei,Chiu Hsiling^ORCID,Polonskaia Ann,Danziger Samuel A.,Towfic Fadi,Parker Joel,King Rebecca L.,Link Brian K.,Slager Susan L.^ORCID,Sarangi Vivekananda,Asmann Yan W.,Novak Joseph P.,Sudhindra Akshay,Ansell Stephen M.^ORCID,Habermann Thomas M.^ORCID,Hagner Patrick R.,Nowakowski Grzegorz S.,Cerhan James R.^ORCID,Novak Anne J.^ORCID,Gandhi Anita K.

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41467-024-50830-y.pdf

Reference58 articles.

1. Teras, L. R. et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. Cancer J. Clin. 66, 443–459 (2016).

2. Sehn, L. & Salles, G. Diffuse large B-cell lymphoma. N. Engl. J. Med. 384, 842–858 (2021).

3. Scott, D. W. et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. J. Am. Soc. Hematol. 131, 2060–2064 (2018).

4. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).

5. Nowakowski, G. S. et al. ROBUST: A phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J. Clin. Oncol. 39, 1317 (2021).